Cramer's Wall St. Confidential: Not Trusting Energy

Apart from believing "the drug companies spread around the money and are very good lobbyists," Cramer feels Medicare Part D has worked.

Concerning the rebound in tech stocks, Cramer said he believes the analysts have been "far more negative than the companies."

He looks at the current situation as a five-week buying opportunity head of Microsoft (MSFT Quote) launching its Vista product. Cramer said he sees "no reason to abandon the group and far more reasons to get behind it."

Moreover, he called Motorola (MOT Quote) "a problem company" and said he is "sick and tired" of Tellabs (TLAB Quote) blaming its underperformance on integration in the telco sector.

It's obvious that Tellabs doesn't have a product portfolio, and with Motorola it's a "leadership issue," where the CEO Ed Zander has been "curiously absent," Cramer said. People should also keep in mind that Motorola is Sprint's (S Quote) biggest supplier and that Sprint has been inconsistent, he said.

Although the first half of the year is seasonally tough for biotechs, Cramer told Task he believes these stocks could "play catch up with pharma, which has been moving better."

Cramer believes this because the sector's major players, Amgen (AMGN Quote) and Genentech (DNA Quote), underperformed in the second half of 2006.

However, because Cramer believes it is a hard group to invest in, he advised buying the biotechs in a basket.